Category: Previous G-BA decisions

Here are the latest G-BA decisions from the G-BA meeting held on 3 July 2025 on the early benefit assessments of Casgevy, Palforzia, and Tagrisso. A complete database of all previous G-BA resolutions is in my membership. Casgevy (exagamglogen autotemcel): ​beta-thalassemia, transfusion-dependent, ≥ 12 years, no HLA-compatible related stem cell donation available – Orphan drug, Indication…

Here are the latest G-BA decisions from the G-BA meeting held on 18 June 2025 on the early benefit assessments of Cerdelga, Balversa, Tevimbra (6 indications!), and Hepcludex. A complete database of all previous G-BA resolutions is in my membership. ​Cerdelga (eliglustat): new indication: Gaucher disease type 1, ≥ 6 to < 18 years, ≥ 15…

Here are the latest G-BA decisions from the G-BA meeting held on 5 June 2025 on the early benefit assessments of Elahere, Kisqali, and Yselty. A complete database of all previous G-BA resolutions is in my membership. ​​Elahere (mirvetuximab soravtansine); 0varian cancer, fallopian tube cancer, or primary peritoneal cancer, FRα-positive, platinum-resistant, after 1 to 3 prior…

Here are the latest G-BA decisions from the G-BA meeting held on 15 May 2025 on the early benefit assessments of Zavicefta, Cravykti, Keytruda, Darzalex, Fasenra, Dupixent and Otezla. A complete database of all previous G-BA resolutions is in my membership. ​Zavicefta (ceftazidime/avibactam); new indication: Bacterial infections, multiple indications, from birth to < 3 months – Reserve…

Here are the latest G-BA decisions from the G-BA meeting held on 17 April 2025 on the early benefit assessments of Vaborem, Vyloy, Artesunate Amivas, and Tepkinly. A complete database of all previous G-BA resolutions is in my membership. ​Vaborem (meropenem/vaborbactam); bacterial infections, multiple indications – Reserve antibiotic, Additional benefit deemed proven across all 5 subgroups ​Vyloy (zolbetuximab);…

Here are the latest G-BA decisions from the G-BA meeting held on 3 April 2025 on the early benefit assessments of Keytruda, Padcev, Truqap, Iqirvo, Anzupgo, and Ocaliva. A complete database of all previous G-BA resolutions is in my membership. ​Keytruda (pembrolizumab); new indication: unresectable or metastatic urothelial carcinoma, first-line, in combination with Padvec – Indication of…

Here are the latest G-BA decisions from the G-BA meeting held on 20 March 2025 on the early benefit assessments of Tecentriq, Keytruda, Cresemba, Akantior, Braftovi, Mektovi, Rybelsus/Ozempic and the RWE decision on Fabhalta. A complete database of all previous G-BA resolutions is in my membership. Tecentriq (atezolizumab) ​reassessment after expiry of previous resolution: non-small…

Here are the latest G-BA decisions from the G-BA meeting held on 6 March 2025 on the early benefit assessments of Winrevair, Yselty, Tepkinly, and Piasky. A complete database of all previous G-BA resolutions is in my membership. ​​Winrevair (sotatercept); pulmonary arterial hypertension – Orphan drug, but manufacturer requested full assessment – Hint of minor additional benefit…

Here are the latest G-BA decisions from the G-BA meeting held on 20 February 2025 on the early benefit assessments of Emblaveo, Adzynma, Lynparza, Imfinzi, Awiqli, Skyrizi, Vabysmo, and Beyfortus. A complete database of all previous G-BA resolutions is in my membership. ​Emblaveo (aztreonam/avibactam); bacterial infections, multiple indications) – Reserve antibiotic, thus additional benefit is deemed proven…

Here are the latest G-BA decisions from the G-BA meeting held on 16 January 2025 on the early benefit assessments of Alecensa, Locametz, Fruzaqla, Eladynos, Soolantra, Zynlonta, Columvi, and Tepkinly. We are starting with very note-worthy decision on Alecensa and a decision on radiodiagnostic Locametz. A complete database of all previous G-BA resolutions is in…